Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP eradication plus palliative therapy in advanced gastric cancer
ChiCTR2500105962Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amoxicillin, clarithromycin and bismuth subcitrate in gastric adenocarcinoma and Helicobacter pylori infection (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-Free Survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
amoxicillinclarithromycinbismuth subcitrate
03
Conditions
gastric adenocarcinomaHelicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500105962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105962.